Bivalent DNA Aptamer Linker Design for Reversible Thrombin Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies, such as heparin and argatroban, suffer from significant side effects and lack a reliable neutralizing agent, while existing thrombin aptamers face challenges in achieving optimal anticoagulant activity and stability, particularly in binding to specific thrombin exosites.
Innovation Solution
Development of monovalent and bivalent nucleic acid aptamers with specific primary structures, utilizing a highly fixed and linear double-stranded DNA linker, to enhance binding to thrombin exosites I and II, thereby inhibiting blood coagulation effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If heparin is used as an anticoagulant, then anticoagulant ability is improved, but serious side effects occur
Solution Approach 1:
The patent uses aptamers (short-lived, degradable nucleic acid molecules) as alternatives to heparin. These aptamers can be designed to have controlled half-lives and can be metabolized by nucleases in the body, reducing accumulation and long-term side effects while maintaining effective anticoagulation during their active period.
Solution Approach 2:
The patent modifies the chemical structure of aptamers through various substitutions (2'-O-methyl, 2'-fluoro, phosphorothioate backbone) to optimize the balance between anticoagulant activity and reduced immunogenicity/toxicity. By changing structural parameters, the aptamers achieve high affinity for thrombin while minimizing harmful interactions with biological systems.
2Reliability
If argatroban is used as an anticoagulant, then anticoagulant ability is improved, but no neutralizing agent exists for reversing drug effects
Solution Approach 1:
The patent extracts the anticoagulant function from irreversible small molecule drugs and implements it through reversible nucleic acid aptamers. The aptamers bind to thrombin through non-covalent interactions (hydrogen bonds, van der Waals forces), allowing the anticoagulant effect to be reversed by removing the aptamer through renal filtration or by administering complementary strands that displace the therapeutic aptamer from thrombin.
3Reliability
If existing thrombin aptamers are used, then anticoagulant activity is achieved, but optimal stability and binding are not reached
Solution Approach 1:
The patent creates composite aptamer structures by combining different nucleic acid modifications (2'-O-methyl ribose, 2'-fluoro substitution, phosphorothioate backbone) with specific sequence designs. These composite structures provide enhanced thermal stability, resistance to nucleases, and optimized binding affinity to thrombin exosites, solving the stability-activity balance problem.
Solution Approach 2:
The patent designs aptamers with dynamic structures that can adapt to thrombin binding. The aptamers contain flexible regions and structured regions (G-quadruplexes, hairpins) that can undergo conformational changes to optimize binding while maintaining stability. The single-stranded to double-stranded transitions in linker regions provide dynamic adaptability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new aptamers demonstrate superior anticoagulant activity and stability, offering a potential solution to the limitations of existing therapies by providing a more effective and controllable anticoagulant with a neutralizing agent.
Implementation Method 1
a neutralizing agent for a pharmaceutical composition for inhibiting blood coagulation, wherein the pharmaceutical composition comprises the bivalent DNA aptamer, and the neutralizing agent comprises a nucleic acid comprising a complementary sequence
Data Source
Figure 1
Figure 2a~2b
Figure 3a~3c
AI summary
The present invention provides a bivalent DNA aptamer and pharmaceutical use thereof. In the bivalent DNA aptamer, a DNA aptamer that binds to exosite I of thrombin and a DNA aptamer that binds to exosite II are linked via a double-stranded DNA.